Amneal Pharmaceuticals has released four new generic drugs, including an anti-anxiety medication, an antidepressant and a pair of allergy medicines.


Amneal Pharmaceuticals, lorazepam, meclizine HCl, promethazine HCl, venlafaxine HCl , generic drugs, Ativa, Effexor, Antivert, Phenergan, Pfizer, Sandoz, Chirag Patel




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Amneal ships four new generics

August 2nd, 2011

BRIDGEWATER, N.J. – Amneal Pharmaceuticals has released four new generic drugs, including an anti-anxiety medication, an antidepressant and a pair of allergy medicines.

The generic pharmaceutical company said Tuesday that the new products — lorazepam, meclizine HCl, promethazine HCl and venlafaxine HCl — all come in tablet form and are now shipping to pharmacies and distributors.

The lorazepam tablets are available in 0.5 mg, 1 mg and 2 mg strengths, each offered in 100-, 500- and 1000-count sizes. Amneal reported that its lorazepam generic is an AB-rated, therapeutically equivalent alternative to Pfizer Inc.'s anti-anxiety drug Ativa.

Meanwhile, the venlafaxine HCl tablets come in dosages of 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg, each in a 90-count bottle. The antidepressant is an AB-rated, therapeutically equivalent alternative to Pfizer's antidepressant Effexor, according to Amneal.

Of the two new allergy treatments, the meclizine HCl tablets are available in 12.5 mg and 25 mg strengths in 100-, 500- and 1,000-count bottles. The Amneal product is an AA-rated, therapeutically equivalent alternative to Pfizer's antihistamine Antivert.

The other antihistamine, promethazine HCl tablets, come in dosages of 12.5 mg in 100-count bottles, 25 mg in 100- and 1000-count sizes, and 50 mg in 100-count bottles. The generic is an AB-rated, therapeutically equivalent alternative to Sandoz's Phenergan.

"We are very pleased with the addition of these four new products to Amneal’s portfolio and our continued aggressive growth," stated Chirag Patel, Amneal's president. "Going forward, the pace will accelerate as we add several new dosage forms, introduce complex and unique products and realize the results of our dramatically expanded R&D team."

Advertisement